Ann: Quarterly Activities Report and Appendix 4C, page-106

Respiratory consultation are the most common consultation performed by doctors world wide so this is a massive market, ResAppDx need to be use so doctor can receive all the information to provide the best care for their patient along with stethoscope, questionnaire and physical examination processes. No diagnose is 100% especially respiratory related which is known to be very difficult for doctor so they need to use all available medical devices at their disposal to assist them. Whether ResAppDx conflict with their initial diagnostic and they dismiss the result is irrelevant, the point is they are using all available tools which might result in them re-testing the stethoscope, questionnaire or physical examination to allow them to arrive at the most possible correct diagnostic.

Then there is respiratory management for Asthma and COPD product which will be a DTC product using RAP's clinical approved wearable device to objectively allow patient to screen if they are having an attack. This will save the government and employers a lot of money in hospitalisation from medication overdose so this will be another massive market.

There currently isn't any competitor for ResAppDx in the acute respiratory diagnostic market, as for the respiratory management market, the portable spirometry currently can be used to screen for Asthma and COPD attacks for patient but this is very inconvenient to use compared to RAP's product.

IMO, RAP can be a $1B MC but those others companies MC are probably $10B+ given their product and market.